Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by johnny007on Apr 22, 2021 11:53am
178 Views
Post# 33044998

RE:Good discovery

RE:Good discoveryNail, I give you one thing here (throw bone).

If Health Clinic has been 'cleaned up' before the merger
as hinted in today's presentation (I missed it, btw - is there a transcript or recording? At which minute did he gave the 'cash positive' balance sheet info?),
and the upcoming Bloomberg TV show report is good
you might be lucky at this price and MCAP.

It is all about perception, that's a given.

CEO needs to brush up his presentations.
I would also say, add more credibility to Aristotle.
The one conference presentation and trial was good,
but it needs more IMHO.
They could layout plans for exactly this, increase market acceptance.

If they manage to brush away fears of the acquisition
by showing a no loss biz (sort of a reverse merger),
then you won IMHO.

200dma of 0.836 should be recovered before the show on BB
to make it look good.

Good luck!

PS: And if you get Clarus saying something with more confidence now,
congratulations.

Over and out.

Nailbiter1 wrote: 10,000 patients with Care Oncology, not 3000.
Our partner is cash positive so we are not taking on their debt.
Start making money on start.
They are associated with huge groups like Cedars Sinai in LA.


<< Previous
Bullboard Posts
Next >>